Actavis and Adamas Announce FDA Approval of Namzaric (memantine/donepezil) for Alzheimer’s Disease

DUBLIN and EMERYVILLE, Calif., Dec. 24, 2014 /PRNewswire/ — Actavis plc (NYSE: ACT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for… – New Drug Approvals

Pharmaceutical Stocks


© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us